Axsome Therapeutics Soars 13.81% Despite Regulatory Delays

On June 12, 2025, Axsome Therapeutics' stock surged by 13.81% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Axsome Therapeutics is currently facing regulatory challenges that have delayed the potential launch of its drug AXS-14 by at least 12-18 months. This setback pushes the commercialization timeline into late 2026 or 2027, deferring expected revenue and impacting the company's near-term financial outlook.

Despite these hurdles, some analysts remain optimistic about Axsome Therapeutics' long-term prospects. They view the current regulatory delays as short-term obstacles that the company can overcome, given its strong pipeline and innovative approach to drug development.